Customer Use Case
- Objective
- Intelligencia's Advantage
- Impact
Download PDF
Objective
A top-10 pharmaceutical company had been developing a combination PD-1/chemotherapy treatment for melanoma. Phase 1 had been completed, and the team was looking into potential options for the Phase 2 program.
Previously, the company had relied on its own expertise, input from KOLs, and clinical trial consultants (to compile, for example, relevant benchmarks related to trial design). The internal R&D analytics team was also performing simulations on trial design.
Previously, the company had relied on its own expertise, input from KOLs, and clinical trial consultants (to compile, for example, relevant benchmarks related to trial design). The internal R&D analytics team was also performing simulations on trial design.
Objective
A top-10 pharmaceutical company had been developing a combination PD-1/chemotherapy treatment for melanoma. Phase 1 had been completed, and the team was looking into potential options for the Phase 2 program.
Previously, the company had relied on its own expertise, input from KOLs, and clinical trial consultants (to compile, for example, relevant benchmarks related to trial design). The internal R&D analytics team was also performing simulations on trial design.
Previously, the company had relied on its own expertise, input from KOLs, and clinical trial consultants (to compile, for example, relevant benchmarks related to trial design). The internal R&D analytics team was also performing simulations on trial design.
Intelligencia's Advantage
Intelligencia’s Asset Optimizer runs predictive analytics and sensitivity analyses on hundreds of parameters to enable users to build trial design scenarios testing key drivers such as:
- Use of endpoints
- Patients (number, inclusion/exclusion criteria)
- Number of arms
- Use of biomarkers
- Timeline
- Indication and TA
- Modality, target, MoA
- Phase, line of treatment
Impact
+25%
Increase in the probability of phase transition by refining the choice of endpoints and the number of arms in the Phase 2 program
+60%
Faster assessment of sensitivity scenarios compared to other methods
+40%
Additional parameters that can be assessed through sensitivity scenarios with our platform
Download PDF
